In an effort to overcome the evasion of B-ALL from CAR-T therapy, Ramakrishna et al., demonstrated that bryostatin is able to upregulate CD22, and to improve outcomes in a NSG animal model system (13). This evidence concerns the gene CD22 and acute lymphoblastic leukemia.